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Patients with type 2 diabetes mellitus (T2DM) are at high risk 
for coronary heart disease, cerebrovascular disease or stroke, 
and peripheral vascular disease. These macrovascular diseases 
are common causes of morbidity and mortality among people 
with diabetes [1,2]. Therefore, there has been considerable 
clinical interest in the development of novel biomarkers that 
may help in the detection of individuals at high risk for cardio-
vascular diseases [3].
  In a recent issue of Diabetes & Metabolism Journal, Kim and 
colleagues presented an article regarding basal C-peptide level 
as a surrogate marker of subclinical atherosclerosis in type 2 
diabetic patients [4]. The authors found a simple positive cor-
relation between basal C-peptide and intima-media thickness 
(IMT). The multiple regression analysis also showed that basal 
C-peptide significantly correlated with IMT (P=0.043) but did 
not correlate with the ten-year coronary heart disease (CHD) 
risk as defined by the United Kingdom Prospective Diabetes 
Study (UKPDS) risk engine (P=0.226). The study concluded 
that basal C-peptide was related to cardiovascular predictors 
(IMT) of T2DM, suggesting that basal C-peptide provides a 
further indication of cardiovascular disease.
  Although it yielded interesting results, the study by Kim et 
al. left some questions to be answered. The relationships be-
tween insulin or C-peptide and atherosclerosis or the risk of 
cardiovascular disease are controversial. The result of their study 
was consistent with those of previous studies that showed that 
levels of fasting plasma proinsulin, C-peptide, and insulin due 
to cross-reacting RIA were associated with common carotid 
artery IMT independent of several conventional risk factors 
for atherosclerosis [5]. However, some studies have reported 
that C-peptide level was associated with diabetic microvascu-
lar but not macrovascular complications in patients with 
T2DM [6]. Others have reported that early thickening and 
damage to the arterial wall in T2DM might be related to rela-
tive fasting hypoinsulinaemia [7]. 
  These differences in results may be originated to differences 
in the clinical characteristics of the study subjects. In the pres-
ent study, the IMT measurement was performed in hospital-
ized patients in only one of two involved institutes. Kim et al. 
did not explain how many subjects were included in IMT mea-
surement or whether there were differences in the clinical char-
acteristics between those who underwent IMT measurement 
and those who did not.
  As mentioned, basal C-peptide level has a strong associa-
tion with insulin resistance and is a better surrogate than insu-
lin for estimating insulin resistance. In the present study, how-
ever, C-peptide level had a simple negative correlation with 
HbA1c, suggesting that glycemic control in the more insulin-
resistant patients was more intensive. Selvin et al. [8] reported 
several important associations between A1C and known risk 
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factors for cardiovascular disease and suggested that A1C is 
independently related to carotid IMT. Kim et al. [2] also report-
ed that changes in the mean IMT correlated with average val-
ues of HbA1c (r=0.219, P=0.007) in Korean type 2 diabetic 
patients, whereas the present study reported that HbA1c, a 
possible risk factor of cardiovascular diseases, did not corre-
late with IMT. It could influence the result that C-peptide did 
not correlate with the ten-year CHD risk according to the UK-
PDS risk engine, although it correlated with IMT, a cardiovas-
cular predictor of T2DM.
  Although their study had some limitations, this study of 
Kim and colleagues is an important work because they not 
only suggested a candidate surrogate marker of atherosclerosis 
in T2DM patients, but also illustrated the role of insulin in the 
pathogenesis of atherosclerosis in T2DM. We greatly appreci-
ate the efforts of the authors in conducting such an intriguing 
work.
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